Pharmacological profiles of selective non-peptidic δ opioid receptor ligands

Molecular Brain Research

Volumn 80, Issue 2, 2000, Pages 166-176

  Chaturvedi, Kirti ^a   Jiang, Xiuju ^a   Christoffers, Keith H ^a   Chinen, Norihiro ^a   Bandari, Persis ^a   Raveglia, Luca F ^b   Ronzoni, Silvano ^b   Dondio, Giulio ^b   Howells, Richard D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b SmithKline Beecham SpA   (Italy)

Author keywords

Delta opioid receptor; G protein coupled receptor; MAP kinase; Morphine; Opioid peptide; Receptor down regulation

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; SB 219825; SB 222941; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION;

AMINO ACID SEQUENCE; ANALGESICS; ANALGESICS, OPIOID; BENZOMORPHANS; BINDING, COMPETITIVE; CELLS, CULTURED; CLONING, MOLECULAR; DOWN-REGULATION; ENKEPHALIN, LEUCINE-2-ALANINE; GTP-BINDING PROTEINS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INDOLES; ISOQUINOLINES; KIDNEY; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; MORPHINE; MUTAGENESIS, SITE-DIRECTED; NALOXONE; NARCOTIC ANTAGONISTS; QUINOLINES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; TRITIUM;

EID: 0034665811     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(00)00134-0     Document Type: Article

References (39)

1. Befort K., Tabbara L., Bausch S., Chavkin C., Evans C., Kieffer B. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49:1996;216-223.
2. Befort K., Tabbara L., Kling D., Maigret B., Kieffer B. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J. Biol. Chem. 271:1996;10161-10168.
3. Befort K., Zilliox C., Filliol D., Yue S., Kieffer B.L. Constitutive activation of the δ opioid receptor by mutations in transmembrane domains III and VII. J. Biol. Chem. 274:1999;18574-18581.
4. Bryant S.D., Salvadori S., Cooper P.S., Lazarus L.H. New δ-opioid antagonists as pharmacological probes. Trends Pharmacol. Sci. 19:1998;42-46.
5. Burkey T.H., Ehlert F.J., Hosohata Y., Quock R.M., Cowells S., Hosohata K., Varga E., Stropova D., Li X., Slate C., Nagase H., Porreca F., Hruby V.J., Roeske W.R., Yamamura H.I. The efficacy of delta-opioid receptor-selective drugs. Life Sci. 62:1998;1531-1536.
6. Burt A.R., Carr I.C., Mullaney I., Anderson N.G., Milligan G. Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse δ opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochem. J. 320:1996;227-235.
7. Calderon S.N., Rothman R.B., Porreca F., Flippen-Anderson J.L., McNutt R.W., Xu H., Smith L.E., Bilsky E.J., Davis P., Rice K.C. Probes for narcotic receptor phenomena. 19. Synthesis of (+)-4-[(αR)-α((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide δ opioid receptor agonist. J. Med. Chem. 37:1994;2125-2128.
8. Chakrabarti S., Yang W., Law P.-Y., Loh H.H. The μ-opioid receptor down-regulates differently from the δ-opioid receptor: requirement of a high affinity receptor/G protein complex formation. Mol. Pharmacol. 52:1997;105-113.
9. Chang K.-J., Rigdon G.C., Howard J.L., McNutt R.W. A novel, potent and selective non-peptide delta-receptor agonist BW373U86. J. Pharmacol. Exp. Ther. 267:1993;852-857.
10. Chaturvedi K., Shahrestanifar M., Howells R.D. μ Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity. Mol. Brain Res. 76:2000;64-72.
11. Claude P.A., Wotta D.R., Zhang X.H., Prather P.L., McGinn T.M., Erickson L.J., Loh H.H., Law P.Y. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc. Natl. Acad. Sci. USA. 93:1996;5715-5719.
12. Comer S.D., Hoenicke E.M., Sable S.I., McNutt R.W., Chang K.-J., Costa B.R.D., Mosberg H.I., Woods J.H. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J. Pharmacol. Exp. Ther. 267:1993;888-895.
13. Dondio G., Clarke G.D., Giardina G., Petrillo P., Petrone G., Ronzoni S., Visentin L., Vecchietti V. The role of the 'spacer' in the octahydroisoquinoline series: discovery of SB 213698, a non-peptidic, potent and selective delta opioid agonist. Analgesia. 1:1995;394-399.
14. Dondio G., Ronzoni S., DesJarlais R.L., Raveglia L.F. Pyrrolooctahydroisoquinolines as potent and selective δ opioid receptor ligands: SAR analysis and docking studies. Bioorg. Med. Chem. Lett. 7:1997;2967-2972.
15. Dondio G., Ronzoni S., Eggleston D.S., Artico M., Petrillo P., Petrone G., Visentin L., Farina C., Vecchietti V., Clarke G.D. Discovery of a novel class of substituted pyrrolooctahydroisoquinolines as potent and selective δ opioid agonists, based on an extension of the message-address concept. J. Med. Chem. 40:1997;3192-3198.
16. Fukuda K., Kato S., Mori K. Location of regions of the opioid receptor involved in selective agonist binding. J. Biol. Chem. 270:1995;6702-6709.
17. Hjorth S.A., Thirstrup K., Grandy D.K., Schwartz T.W. Analysis of selective binding epitopes for the κ-opioid receptor antagonist nor-binaltorphimine. Mol. Pharmacol. 47:1995;1089-1094.
18. Hong E.J., Rice K.C., Calderon S.N., Woods J.H., Traynor J.R. Convulsive behavior of nonpeptide δ-opioid ligands: comparison of SNC80 and BW373U86 in mice. Analgesia. 3:1998;269-276.
19. Jordan B.A., Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature. 399:1999;697-700.
20. Kamei J., Saitoh A., Ohsawa M., Suzuki T., Misawa M., Nagase H., Kasuya Y. Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice. Eur. J. Pharmacol. 276:1995;131-135.
21. Knapp R.J., Landsman R., Waite S., Malatynska E., Varga E., Haq W., Hruby V.J., Roeske W.R., Nagase H., Yamamura H.I. Properties of TAN-67, a nonpeptidic δ-opioid receptor agonist, at cloned human δ- and μ-opioid receptors. Eur. J. Pharmacol. 291:1995;129-134.
22. Kong H., Raynor K., Yasuda K., Moe S.T., Portoghese P.S., Bell G.I., Reisine T. A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268:1993;23055-23058.
23. Loh H.H., Liu H.C., Cavalli A., Yang W., Chen Y.F., Wei L.N. μ Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Mol. Brain Res. 54:1998;321-326.
24. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., Le Meur M., Dolle P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature. 383:1996;819-823.
25. Meng F., Hoversten M.T., Thompson R.C., Taylor L., Watson S.J., Akil H. A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ opioid receptors. J. Biol. Chem. 270:1995;12730-12736.
26. Meng F., Ueda Y., Hoversten M.T., Thompson R.C., Taylor L., Watson S.J., Akil H. Mapping the receptor domains critical for the binding selectivity of δ-opioid receptor ligands. Eur. J. Pharmacol. 311:1996;285-292.
27. Millan M.J. Kappa-opioid receptors and analgesia. Trends Pharmacol. Sci. 11:1990;70-76.
28. 5]enkephalin from binding to the δ-opioid receptor. Mol. Pharmacol. 50:1996;1413-1422.
29. Pepin M.-C., Yue S.Y., Roberts E., Wahlestedt C., Walker P. Novel 'restoration of function' mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J. Biol. Chem. 272:1997;9260-9267.
30. Portoghese P.S., Sultana M., Takemori A.E. Design of peptidomimetic δ opioid receptor antagonists using the message-address concept. J. Med. Chem. 33:1990;1714-1720.
31. Shahrestanifar M., Howells R.D. Sensitivity of opioid receptor binding to N-substituted maleimides and methanethiosulfonate derivatives. Neurochem. Res. 21:1996;1295-1299.
32. Shahrestanifar M., Wang W.W., Howells R.D. Studies on inhibition of μ and δ opioid receptor binding by dithiothreitol and N-ethylmaleimide. J. Biol. Chem. 271:1996;5505-5512.
33. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA. 94:1997;1544-1549.
34. Payne D.M., Rossomando A.J., Martino P., Erickson A.K., Her J.-H., Shabanowitz J., Hunt D.F., Weber M.J., Sturgill T.W. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10:1991;885-892.
35. Takemori A.E., Portoghese P.S. Selective naltrexone-derived opioid receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 32:1992;239-269.
36. Valiquette M., Vu H.K., Yue S.Y., Wahlestedt C., Walker P. Involvement of Trp-284, Val-296, and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands. J. Biol. Chem. 271:1996;18789-18796.
37. Wang W.W., Shahrestanifar M., Jin J., Howells R.D. Studies on μ and δ opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc. Natl. Acad. Sci. USA. 92:1995;12436-12440.
38. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol. Ther. 80:1998;231-264.
39. Wild K.D., McCormick J., Bilsky E.J., Vanderah T.W., McNutt R.W., Chang K.-J., Porreca F. Antinociceptive actions of BW373U86 in the mouse. J. Pharmacol. Exp. Ther. 267:1993;858-865.